The effect of amiloride in decreasing albuminuria in patients with diabetic kidney diseases: a prospective, crossover, open-label study

References

• Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382(9888):260–272.
   PubMed Web of Science ®Google Scholar
• Zhang L, Long J, Jiang W, et al. Trends in chronic kidney disease in China. N Engl J Med. 2016;375(9):905–906.
   PubMed Web of Science ®Google Scholar
• Alsaad KO, Herzenberg AM. Distinguishing diabetic nephropathy from other causes of glomerulosclerosis: an update. J Clin Pathol. 2007;60(1):18–26.
   PubMed Web of Science ®Google Scholar
• Gunzler D, Bleyer AJ, Thomas RL, et al. Diabetic nephropathy in a sibling and albuminuria predict early GFR decline: a prospective cohort study. BMC Nephrol. 2013;14:124.
   PubMed Web of Science ®Google Scholar
• Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073–2081.
   PubMed Web of Science ®Google Scholar
• de Zeeuw D. Albuminuria: a target for treatment of type 2 diabetic nephropathy. Semin Nephrol. 2007;27(2):172–181.
   PubMed Web of Science ®Google Scholar
• Podgórski P, Konieczny A, Lis Ł, et al. Glomerular podocytes in diabetic renal disease. Adv Clin Exp Med. 2019;28(12):1711–1715.
   PubMed Web of Science ®Google Scholar
• Faul C, Donnelly M, Merscher-Gomez S, et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med. 2008;14(9):931–938.
   PubMed Web of Science ®Google Scholar
• Reiser J, Oh J, Shirato I, et al. Podocyte migration during nephrotic syndrome requires a coordinated interplay between cathepsin L and alpha3 integrin. J Biol Chem. 2004;279(33):34827–34832.
   PubMed Web of Science ®Google Scholar
• Asanuma K, Yanagida-Asanuma E, Faul C, et al. Synaptopodin orchestrates actin organization and cell motility via regulation of RhoA signalling. Nat Cell Biol. 2006;8(5):485–491.
   PubMed Web of Science ®Google Scholar
• Wei C, Möller CC, Altintas MM, et al. Modification of kidney barrier function by the urokinase receptor. Nat Med. 2008;14(1):55–63.
   PubMed Web of Science ®Google Scholar
• Blasi F, Carmeliet P. uPAR: a versatile signaling orchestrator. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol. 2002;3(12):932–943.
   PubMed Web of Science ®Google Scholar
• Wei C, El Hindi S, Li J, et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med. 2011;17(8):952–960.
   PubMed Web of Science ®Google Scholar
• Zhang B, Xie S, Shi W, et al. Amiloride off-target effect inhibits podocyte urokinase receptor expression and reduces proteinuria. Nephrol Dial Transplant. 2012;27(5):1746–1755.
   PubMed Web of Science ®Google Scholar
• Staehr M, Buhl KB, Andersen RF, et al. Aberrant glomerular filtration of urokinase-type plasminogen activator in nephrotic syndrome leads to amiloride-sensitive plasminogen activation in urine. Am J Physiol Renal Physiol. 2015;309(3):F235–F241.
   PubMed Web of Science ®Google Scholar
• Parving HH, Mauer M, Fioretto P, et al. Diabetic nephropathy. In: Brenner B, editor. Brenner and Rector’s the kidney. Vol. 1. Philadelphia (PA): Elsevier; 2012. p. 1411–1454.
   Google Scholar
• Persson F, Rossing P. Diagnosis of diabetic kidney disease: state of the art and future perspective. Kidney Int Suppl. 2018;8(1):2–7.
   Web of Science ®Google Scholar
• Bailey RA, Wang Y, Zhu V, et al. Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging. BMC Res Notes. 2014;7(1):415.
   PubMedGoogle Scholar
• Afkarian M, Sachs MC, Kestenbaum B, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol. 2013;24(2):302–308.
   PubMed Web of Science ®Google Scholar
• Patrakka J, Tryggvason K. New insights into the role of podocytes in proteinuria. Nat Rev Nephrol. 2009;5(8):463–468.
   PubMed Web of Science ®Google Scholar
• Brinkkoetter PT, Ising C, Benzing T. The role of the podocyte in albumin filtration. Nat Rev Nephrol. 2013;9(6):328–336.
   PubMed Web of Science ®Google Scholar
• Okamura K, Dummer P, Kopp J, et al. Endocytosis of albumin by podocytes elicits an inflammatory response and induces apoptotic cell death. PLoS One. 2013;8(1):e54817.
   PubMed Web of Science ®Google Scholar
• Kestilä M, Lenkkeri U, Männikkö M, et al. Positionally cloned gene for a novel glomerular protein–nephrin–is mutated in congenital nephrotic syndrome. Mol Cell. 1998;1(4):575–582.
   PubMed Web of Science ®Google Scholar
• Shankland SJ. The podocyte’s response to injury: role in proteinuria and glomerulosclerosis. Kidney Int. 2006;69(12):2131–2147.
   PubMed Web of Science ®Google Scholar
• Tryggvason K, Patrakka J, Wartiovaara J. Hereditary proteinuria syndromes and mechanisms of proteinuria. N Engl J Med. 2006;354(13):1387–1401.
   PubMed Web of Science ®Google Scholar
• Asanuma K, Yanagida-Asanuma E, Takagi M, et al. The role of podocytes in proteinuria. Nephrology. 2007;12(3):S15–S20.
   PubMedGoogle Scholar
• Huang J, Liu G, Zhang YM, et al. Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis. BMC Med. 2014;12(1):81.
   PubMedGoogle Scholar
• Edwards S, Lalor PF, Tuncer C, et al. Vitronectin in human hepatic tumours contributes to the recruitment of lymphocytes in an alpha v beta3-independent manner. Br J Cancer. 2006;95(11):1545–1554.
   PubMed Web of Science ®Google Scholar
• Wu S, Murrell GA, Wang Y. Interferon-alpha (Intron A) upregulates urokinase-type plasminogen activator receptor gene expression. Cancer Immunol Immunother. 2002;51(5):248–254.
   PubMed Web of Science ®Google Scholar
• Wang Y, Jones CJ, Dang J, et al. Human urokinase receptor expression is inhibited by amiloride and induced by tumor necrosis factor and phorbol ester in colon cancer cells. FEBS Lett. 1994;353(2):138–142.
   PubMed Web of Science ®Google Scholar
• Kleyman TR, Cragoe EJ. Jr. Amiloride and its analogs as tools in the study of ion transport. J Membr Biol. 1988;105(1):1–21.
   PubMed Web of Science ®Google Scholar
• Vassalli JD, Belin D. Amiloride selectively inhibits the urokinase-type plasminogen activator. FEBS Lett. 1987;214(1):187–191.
   PubMed Web of Science ®Google Scholar
• Unruh ML, Pankratz VS, Demko JE, et al. Trial of amiloride in type 2 diabetes with proteinuria. Kidney Int Rep. 2017;2(5):893–904.
   PubMed Web of Science ®Google Scholar